Natera, Inc.

Alpha Score of 37 reflects weak overall profile with moderate momentum, poor value, weak quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.

Natera Inc. is a diagnostics company specializing in the discovery, development, and commercialization of genetic testing services powered by proprietary molecular and bioinformatics technology. Its primary offerings include the Panorama non-invasive prenatal test (NIPT), which screens for chromosomal abnormalities in singleton and twin pregnancies via a maternal blood draw; Vistara, an expanded NIPT; Horizon carrier screening (HCS) to assess carrier status for numerous severe genetic diseases; Spectrum for pre-implantation genetic screening and diagnosis; Anora for products of conception analysis; and non-invasive paternity testing. In oncology, Signatera detects circulating tumor DNA to monitor molecular residual disease and cancer recurrence. Prospera evaluates organ transplant rejection risk. These tests serve healthcare providers, patients, and researchers in obstetrics, oncology, transplant medicine, and reproductive genetics, enabling earlier detection, personalized treatment, and improved clinical outcomes. Founded in 2004 and headquartered in Austin, Texas, Natera Inc. plays a pivotal role in advancing precision diagnostics across key medical sectors.